A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 330 participants.

Also called NCT07922330

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 330 participants (planned count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07922330
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China, India (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07922330. Randomized; triple masking; primary purpose treatment. Start 2027-01-04 (anticipated); primary completion 2028-09-15 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Acronym
SELENE-Asia
Condition
Obesity
Condition
Overweight
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
AZD6234
Intervention (Drug)
Placebo
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct07922330
Content hash
ac33ee732d87209e7cb1719209274dc28b0b36d1ea25e927249a4c60c60e69e4